Krishna Institute of Medical Sciences Limited (NSE:KIMS)
India · Delayed Price · Currency is INR 710.80
+10.35 (1.48%)
Feb 19, 2026, 11:10 AM IST
NSE:KIMS Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 36,270 | 30,351 | 24,982 | 21,977 | 16,508 | 13,299 |
| 36,270 | 30,351 | 24,982 | 21,977 | 16,508 | 13,299 | |
Revenue Growth (YoY) | 26.29% | 21.49% | 13.68% | 33.13% | 24.13% | 18.46% |
Cost of Revenue | 14,655 | 12,128 | 10,160 | 8,793 | 6,676 | 5,535 |
Gross Profit | 21,615 | 18,223 | 14,822 | 13,184 | 9,832 | 7,764 |
Selling, General & Admin | 477 | 477 | 495 | 352.46 | 205.01 | 178.24 |
Other Operating Expenses | 13,194 | 9,910 | 7,950 | 6,784 | 4,429 | 3,851 |
Operating Expenses | 16,179 | 12,159 | 9,910 | 8,429 | 5,361 | 4,733 |
Operating Income | 5,436 | 6,064 | 4,912 | 4,755 | 4,471 | 3,031 |
Interest Expense | -1,596 | -887 | -464 | -293.18 | -159.21 | -293.02 |
Interest & Investment Income | 102 | 102 | 23 | 95.32 | 122.82 | 57.99 |
Earnings From Equity Investments | - | - | -3 | - | 95.1 | - |
Other Non Operating Income (Expenses) | 25 | 134 | 70 | 29.43 | 23.15 | -2.9 |
EBT Excluding Unusual Items | 3,967 | 5,413 | 4,538 | 4,586 | 4,553 | 2,793 |
Gain (Loss) on Sale of Investments | 48 | 48 | 41 | 30.01 | - | - |
Gain (Loss) on Sale of Assets | 109 | 109 | 4 | 6.1 | -27.17 | -10.79 |
Other Unusual Items | 8 | 11 | 12 | 226.72 | 42.41 | 7.52 |
Pretax Income | 4,132 | 5,581 | 4,595 | 4,849 | 4,569 | 2,790 |
Income Tax Expense | 982 | 1,433 | 1,236 | 1,191 | 1,131 | 735.36 |
Earnings From Continuing Operations | 3,150 | 4,148 | 3,359 | 3,658 | 3,438 | 2,055 |
Minority Interest in Earnings | -143 | -303 | -259 | -294.91 | -111.1 | -42.6 |
Net Income | 3,007 | 3,845 | 3,100 | 3,363 | 3,327 | 2,012 |
Net Income to Common | 3,007 | 3,845 | 3,100 | 3,363 | 3,327 | 2,012 |
Net Income Growth | -13.63% | 24.03% | -7.83% | 1.09% | 65.33% | 68.83% |
Shares Outstanding (Basic) | 400 | 400 | 400 | 400 | 397 | 374 |
Shares Outstanding (Diluted) | 400 | 400 | 400 | 400 | 397 | 381 |
Shares Change (YoY) | 0.18% | - | - | 0.74% | 4.32% | 1.42% |
EPS (Basic) | 7.51 | 9.61 | 7.75 | 8.41 | 8.38 | 5.37 |
EPS (Diluted) | 7.51 | 9.61 | 7.75 | 8.41 | 8.38 | 5.28 |
EPS Growth | -13.78% | 24.03% | -7.83% | 0.35% | 58.51% | 66.48% |
Free Cash Flow | - | -4,271 | -1,261 | -1,424 | 1,537 | 2,615 |
Free Cash Flow Per Share | - | -10.67 | -3.15 | -3.56 | 3.87 | 6.87 |
Gross Margin | 59.59% | 60.04% | 59.33% | 59.99% | 59.56% | 58.38% |
Operating Margin | 14.99% | 19.98% | 19.66% | 21.63% | 27.09% | 22.79% |
Profit Margin | 8.29% | 12.67% | 12.41% | 15.30% | 20.15% | 15.13% |
Free Cash Flow Margin | - | -14.07% | -5.05% | -6.48% | 9.31% | 19.67% |
EBITDA | 7,061 | 7,544 | 6,199 | 5,828 | 5,120 | 3,661 |
EBITDA Margin | 19.47% | 24.86% | 24.81% | 26.52% | 31.01% | 27.52% |
D&A For EBITDA | 1,625 | 1,480 | 1,287 | 1,073 | 648.09 | 629.24 |
EBIT | 5,436 | 6,064 | 4,912 | 4,755 | 4,471 | 3,031 |
EBIT Margin | 14.99% | 19.98% | 19.66% | 21.63% | 27.09% | 22.79% |
Effective Tax Rate | 23.77% | 25.68% | 26.90% | 24.56% | 24.75% | 26.36% |
Revenue as Reported | 36,480 | 30,670 | 25,143 | 22,236 | 16,711 | 13,401 |
Advertising Expenses | - | 329 | 252 | 197.39 | 111.51 | 91.81 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.